Search
FR
Print page

NEW

Teva-Everolimus

  • Generic name

    everolimus

  • Brand reference

    Afinitor®

  • Strength

    2.5 mg

  • DIN

    02463229

  • Therapeutic class

    Antineoplastic Agent

  • Therapeutic area

    Oncology

  • Package size

    Blister 30

  • Product code

    72100-0127

  • UPC

    068510178527

  • Generic name:

    everolimus

  • Brand reference:

    Afinitor®

  • Product code:

    72100-0127

  • Strength

    2.5 mg

  • DIN

    02463229

  • UPC:

    068510178527

  • Therapeutic class

    Antineoplastic Agent

  • Therapeutic area:

    Oncology

  • Package size:

    Blister 30

Composition

Active ingredient

everolimus


Non-medicinal ingredients

butylhydroxytoluene, crospovidone, hypromellose, lactose anhydrous, lactose monohydrate and magnesium stearate.

Product characteristics

  • Dosage form

    tablet

  • Shape

    oblong

  • Marking 1

    EV

  • Marking 2

    2.5

  • Colour

    white

  • Secondary colour

  • Scored

  • Flavour

  • Gluten

    currently not available

  • Latex

    currently not available

Disclaimers

All information about raw materials and / or allergen information for Teva Canada’s products is obtained from our suppliers and/or third party affiliates and is based on their records.

Please be advised that the Medical Information department is not always notified of change in third party affiliates and / or change in suppliers of the excipients that may occur over time, and all information provided herein is based on our last current records.

"Latex" – refers to NATURAL RUBBER LATEX. We cannot guarantee that there is no latex in the outer packaging or that the medication or packaging haven’t come into contact with latex at any point during the manufacturing process, however this is very unlikely due to the strict GMP procedures that are in place in all of our manufacturing facilities. Employees in the manufacturing and / or packaging facilities may be wearing latex gloves

Product monograph/consumer information leaflet


View monograph

Notice

We are modifying our product names to align with our corporate name change. Accordingly, please expect product monographs to contain the “Novo-”, “ratio-”, “ACT”, "CO" prefix or the new “Teva” prefix. These prefixes may be used interchangeably on the website.

Should you have any questions about our product names or our corporate name change, please do not hesitate to contact us. Our Customer Care department can be reached at 1-800-268-4127 regarding your inquiry.

Caution: You are about to leave the TevaCanada.com website. Click "Continue" to certify that you have read the following communication and view the selected website.

Links to websites not under the control of Teva Canada, including links to social media sites, are provided solely for the convenience of visitors to our website. Teva Canada is not responsible for the accuracy, timeliness, completeness, appropriateness or accuracy of the content of these websites and does not endorse or recommend opinions, ideas, products , the information or the content of these sites. Teva Canada hereby disclaims all liability for all information, materials, products or services without exception that are displayed, offered or made available to visitors of a third party website. As third parties may have a privacy or computer security policy that differs from Teva Canada, please refer to the privacy or security policies of those third parties when accessing their respective websites.